Tonix Pharmaceuticals Reports Increased Q3 Losses Amid Rising Revenue and Upcoming Product Launch

Tonix Pharmaceuticals Holding Corp. reported its financial results for the third quarter and nine months ended September 30, 2025, revealing a net loss of $32.0 million for the quarter, a significant increase from the $14.2 million loss recorded in the same period last year. For the nine-month period, the company reported a net loss of $77.1 million, down from $107.9 million in the prior year. The increase in quarterly losses is attributed to heightened selling, general, and administrative expenses, which surged to $25.7 million from $7.7 million year-over-year, primarily due to increased marketing efforts in anticipation of the upcoming launch of its new product, Tonmya, and additional sales personnel.

Total revenue for the third quarter reached $3.3 million, up from $2.8 million in the same quarter of 2024, driven by increased demand for its migraine treatments, Zembrace SymTouch and Tosymra. For the nine months ended September 30, 2025, total revenue was $7.7 million, slightly higher than the $7.5 million reported for the same period in 2024. The company’s product revenue was bolstered by the performance of its migraine products, with Zembrace generating $6.2 million and Tosymra contributing $1.5 million in the nine-month period.

Tonix's financial position improved significantly, with cash and cash equivalents increasing to $190.1 million as of September 30, 2025, compared to $98.8 million at the end of 2024. The company’s total assets rose to $252.4 million, up from $162.9 million at the end of the previous fiscal year. This increase in liquidity is attributed to successful financing activities, including the issuance of common stock, which provided $155.4 million in net cash during the nine months ended September 30, 2025.

Strategically, Tonix is preparing for the launch of Tonmya, a new treatment for fibromyalgia, which received FDA approval in August 2025. The company plans to launch the product in the U.S. by the end of November 2025. Additionally, Tonix has been active in expanding its product pipeline, with ongoing development in areas such as central nervous system disorders and infectious diseases. The company has also entered into a license agreement with UMass Chan Medical School for the development of TNX-4800, a monoclonal antibody for Lyme disease prevention.

Looking ahead, Tonix anticipates that its operating costs will continue to rise as it aligns resources for the commercial launch of Tonmya. The company acknowledges the need for additional funding to support its operations and product development, emphasizing the importance of a successful launch for Tonmya to secure future financing. The company’s ability to raise capital on favorable terms remains uncertain, and it may need to scale back or delay research and development activities if it cannot secure the necessary funds.